CGAS and neoplasm: Prexasertib treatment increased expression of TBK1, a downstream activator in the cGAS-STING pathway, suggesting enhanced innate immune activation. This pathway potentially contributes to tumor immunogenicity by stimulating type I interferons and promoting immune cell recruitment to tumor sites.